ArticleStem cells international2026
Bone Marrow Mesenchymal Stromal Cells and Their Derived Extracellular Vesicles Protect Pancreatic Beta-TC-6 Cells From Hypoxia-Induced Injury via miR-539-3p-Mediated Downregulation of CD36 Expression.
Article in Stem cells international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Diet and Lipidomics Mediated Regulation of Mesenchymal Stem Cell Function: Diet, Omics and Stem Cell Connection.Biomolecules · 2026Review
- Bone Marrow Mesenchymal Stromal Cells and Their Derived Extracellular Vesicles Protect Pancreatic Beta-TC-6 Cells From Hypoxia-Induced Injury via miR-539-3p-Mediated Downregulation of CD36 Expression.Stem cells international · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bone marrow mesenchymal stromal cells (BMSCs) have been shown to enhance the function of pancreatic beta-cells under hypoxic conditions. However, the precise mechanisms underlying this protective effect remain elusive. In this study, we established a hypoxic beta-cell model using murine pancreatic beta-TC-6 cells to investigate the protective effect and mechanism of BMSCs and their secreted extracellular vesicles (BMSC-EVs) on hypoxic β cells. Our findings reveal that coculture with BMSCs or BMSC-EVs significantly enhances the viability and survival of hypoxic beta-TC-6 cells. Molecularly, hypoxic conditions trigger an upregulation of CD36 in beta-TC-6 cells, a response that is counteracted by BMSCs or BMSC-EVs. Through a screening process for microRNAs (miRNAs) capable of degrading CD36 mRNA, we identified miR-539-3p as a potent suppressor of CD36 expression. The miR-539-3p mimic was found to bolster the viability of hypoxic beta-TC-6 cells, concurrently reducing CD36 mRNA levels by targeting its 3' untranslated region (3'UTR). In contrast, the miR-539-3p inhibitor abrogates the protective effects of BMSCs and BMSC-EVs on these cells. Additionally, knockdown of CD36 in hypoxic beta-TC-6 cells restores the protective function mitigated by miR-539-3p inhibition. In aggregate, these results suggest that BMSCs and BMSC-EVs shield beta-TC-6 cells from hypoxia-induced injury through miR-539-3p-mediated downregulation of CD36, underscoring the therapeutic potential of targeting the miR-539-3p-CD36 axis to enhance pancreatic beta-cell function in diabetic patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.